ALS Archives -

Biogen waves bye to $217m ALS partnership with Karyopharm

Phil Taylor ALS, Biogen, Karyopharm, neurology, partnering 0 Comment

Biogen has ducked out of a four-year-old collaboration with Karyopharm on a drug candidate for the neurodegenerative disease

Biogen waves bye to $217m ALS partnership with Karyopharm

https://pharmaphorum.com/news/biogen-says-bye-to-217m-als-partnership-with-karyopharm/

News/ News/ R&D

New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial

Eloise McLennan ALS, Biogen, clinical trials, Ionis Pharmaceuticals, pharma 0 Comment

Less than six months after the late-stage failure of tofersen, Biogen and Ionis have suffered further disappointment in

New blow for ALS pipeline as Biogen and Ionis candidate fails Phase 1 trial

https://pharmaphorum.com/news/new-blow-for-als-pipeline-as-biogen-and-ionis-candidate-fails-phase-1-trial/

News/ News/ R&D

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

Phil Taylor ALS, Biogen, neurodegenerative disease, tofersen 0 Comment

Already struggling to make headway with its recently launched Alzheimer’s drug, Biogen suffered a major late-stage pipeline setback

Blow to Biogen as ALS hope tofersen flunks phase 3 trial

https://pharmaphorum.com/news/blow-to-biogen-as-als-hope-tofersen-flunks-phase-3-trial/

Digital/ R&D/ Video/ Views & Analysis/ Views & Analysis/ Views and analysis

Health Innovators: Teresa Arroyo-Gallego, nQ Medical

Paul Tunnah ALS, Alzheimer's, artificial intelligence, digital health, health innovators, nQ Medical, Parkinson's 0 Comment

In this episode of our Health Innovators series, Paul Tunnah is joined by Teresa Arroyo-Gallego, chief data scientist

Health Innovators: Teresa Arroyo-Gallego, nQ Medical

https://pharmaphorum.com/video/health-innovators-teresa-arroyo-gallego-nq-medical/

R&D/ Views & Analysis/ Views and analysis

Tackling diabetes & ALS with cell therapy

Catherine Longworth ALS, cell therapy, Diabetes, Kadimastem 0 Comment

Israeli company Kadimastem is developing regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells

Tackling diabetes & ALS with cell therapy

https://pharmaphorum.com/views-and-analysis/tackling-diabetes-als-with-cell-therapy/

Digital/ News/ News/ Top stories

BMS joins forces with insitro to develop neurodegenerative treatments

Catherine Longworth AI, ALS, Bristol-Myers Squibb, drug discovery, FTD, Insitro, machine learning 0 Comment

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies

BMS joins forces with insitro to develop neurodegenerative treatments

https://pharmaphorum.com/news/bms-joins-forces-with-insitro-to-develop-neurodegenerative-treatments/

Partner content/ Partner Content/ Press releases

The ALS patient journey

sophie.berger@bluelatitude.com ALS, ALSAwareness, EndALS, motor neuron disease, Rare diseases 0 Comment

Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease (MND). ALS is a progressive

The ALS patient journey

https://pharmaphorum.com/partner-content/the-als-patient-journey/

Market Access/ News/ News/ Top stories

Mitsubishi Tanabe pulls ALS drug from EMA assessment

George Underwood ALS, ema, Mitsubishi Tanabe, Radicava 0 Comment

Mitsubishi Tanabe Pharma has withdrawn its EU application for ALS drug Radicava (edaravone), citing ‘unwarranted’ additional data requirements

Mitsubishi Tanabe pulls ALS drug from EMA assessment

https://pharmaphorum.com/news/mitsubishi-tanabe-pulls-als-drug-from-ema-assessment/

Digital and Social Media/ News/ R&D

AI-discovered candidates show promise in ALS

Marco Ricci AI, ALS, artificial intelligence, BenevolentAI, motor neurone disease 0 Comment

Candidates slow down motor neurone death in patient samples.

AI-discovered candidates show promise in ALS

https://pharmaphorum.com/news/ai-candidates-motor-neurone-disease/

Trending

ALS

Login